Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival
- PMID: 18156922
- DOI: 10.1097/SLA.0b013e3181571047
Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival
Abstract
Objective: In this prospective randomized trial, we attempted to find out if 1 dose of postoperative adjuvant intra-arterial iodine-131-labeled lipiodol could reduce the rate of local recurrence, and increase disease-free and overall survival for patients with hepatocellular carcinoma (HCC). This study evaluated the long-term outcome.
Background: Resection of HCC is potentially curative, but local recurrence is common. However, there is currently no effective adjuvant therapy. Early results after closing the trial (Lau et al. Lancet 1999;353:797-801) showed that 1 dose of intra-arterial I-lipiodol given after curative resection significantly decreased the rate of recurrence, and increased disease-free and overall survival.
Methods: Patients who underwent curative resection for HCC and recovered within 6 weeks were randomly assigned one 1850 MBq dose of I-lipiodol or no further treatment (controls). We compared rates of recurrence, and long-term disease-free and overall survival (the primary endpoints) between the 2 groups by intention-to-treat.
Results: Between April 1992 and August 1997, we recruited 43 patients: 21 were randomized to receive intra-arterial I-lipiodol and 22 to receive no adjuvant treatment. I-lipiodol had no significant toxic effects. During a median follow-up of 66 (range, 3-198) months, there were 10 (47.6%) recurrences among the 21 patients in the adjuvant treatment group, compared with 14 (63.6%) in the control group (P = 0.29). The actuarial 5-year disease-free survival in the treatment and control groups was 61.9% and 31.8%, respectively (P = 0.0397). The actuarial 5-year overall survival in the treatment and control groups was 66.7% and 36.4%, respectively (P = 0.0433). The actuarial 7-year disease-free survival in the treatment and control groups was 52.4% and 31.8%, respectively (P = 0.0224). The actuarial 7-year overall survival in the treatment and control groups was 66.7% and 31.8%, respectively (P = 0.0243). The actuarial 10-year disease-free survival in the treatment and control groups was 47.6% and 27.3%, respectively (P = 0.0892). The actuarial 10-year overall survival in the treatment and control groups was 52.4% and 27.3%, respectively (P = 0.0905).
Conclusions: In patients with HCC, adjuvant intra-arterial I-lipiodol after curative liver resection provided survival benefit on the disease-free survival and overall survival, although the difference became statistically insignificant at 8 years after randomization.
Similar articles
-
Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up.J Nucl Med. 2008 Mar;49(3):362-6. doi: 10.2967/jnumed.107.044750. Epub 2008 Feb 20. J Nucl Med. 2008. PMID: 18287267
-
Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.Hepatology. 2003 Nov;38(5):1237-41. doi: 10.1053/jhep.2003.50473. Hepatology. 2003. PMID: 14578862
-
Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma.Hepatology. 1997 Nov;26(5):1156-61. doi: 10.1002/hep.510260511. Hepatology. 1997. PMID: 9362356 Clinical Trial.
-
131-iodine Lipiodol therapy in hepatocellular carcinoma.Q J Nucl Med Mol Imaging. 2009 Jun;53(3):348-55. Q J Nucl Med Mol Imaging. 2009. PMID: 19521315 Review.
-
[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].Zentralbl Chir. 2009 Apr;134(2):127-35. doi: 10.1055/s-0028-1098881. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382043 Review. German.
Cited by
-
Current management of hepatocellular carcinoma.World J Gastroenterol. 2014 Aug 14;20(30):10223-37. doi: 10.3748/wjg.v20.i30.10223. World J Gastroenterol. 2014. PMID: 25132740 Free PMC article. Review.
-
Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma.Medicine (Baltimore). 2017 Aug;96(32):e7390. doi: 10.1097/MD.0000000000007390. Medicine (Baltimore). 2017. PMID: 28796032 Free PMC article.
-
Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.World J Surg. 2013 Jun;37(6):1356-61. doi: 10.1007/s00268-013-1970-4. World J Surg. 2013. PMID: 23463394 Clinical Trial.
-
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.World J Gastroenterol. 2019 Jul 28;25(28):3704-3721. doi: 10.3748/wjg.v25.i28.3704. World J Gastroenterol. 2019. PMID: 31391767 Free PMC article. Review.
-
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2. Cochrane Database Syst Rev. 2017. PMID: 28351116 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous